Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase
Open Access
- 1 December 2008
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (49) , 34218-34228
- https://doi.org/10.1074/jbc.m806797200
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsAIDS, 2008
- Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral ChallengeAntimicrobial Agents and Chemotherapy, 2008
- Hepatitis B viruses: Reverse transcription a different wayVirus Research, 2008
- Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptaseVirus Research, 2008
- Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of TenofovirAntimicrobial Agents and Chemotherapy, 2007
- Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B PolymeraseAntimicrobial Agents and Chemotherapy, 2007
- The HBV Drug Entecavir — Effects on HIV-1 Replication and ResistanceNew England Journal of Medicine, 2007
- Inhibition of Hepatitis B Virus Polymerase by EntecavirJournal of Virology, 2007
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Fixed Conformation Nucleoside Analogs Effectively Inhibit Excision-proficient HIV-1 Reverse TranscriptasesJournal of Molecular Biology, 2005